Hummingbird Bioscience CEO Piers Ingram (L) and Synaffix CEO Peter van de Sande

Hum­ming­bird and Synaf­fix agree to an­ti­body-drug con­ju­gate deal worth up to $150M

The Dutch biotech Synaf­fix has been ac­tive on the deal front for the past few years. And it’s not show­ing signs of stop­ping, hit­ting the ground run­ning in 2023 by ink­ing a deal with Sin­ga­pore’s Hum­ming­bird Bio­science.

In an an­nounce­ment Mon­day, Hum­ming­bird and the an­ti­body-drug con­ju­gate biotech said they will en­ter in­to a li­cens­ing agree­ment, open­ing the door for Hum­ming­bird to de­vel­op an ADC pro­gram us­ing Synaf­fix’s tech­nol­o­gy.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.